drugset / Trial / NCT00865267

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865267

Phase 1 Completed 20 enrolled Actavis Inc.
NaSingle-groupSingle-blind

Summary

The purpose of this study is to determine the duration of application of halobetasol propionate 0.05% ointment to be used in a definitive study of bioequivalence of to formulations of this ointment. Part A: To validate vasoconstrictor assay precision. Part B: To evaluate the dose response vasoconstriction profile of Ultravate® 0.05% ointment at different dose durations over a short period of time (0.17 - 4 hrs).

Timeline

Start
2003-12
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject halobetasol propionate Small molecule 0.05 % Topical

Indications

No indication recorded.